Great Bay Bio Announces Its First AI-enabled Bioprocessing Platform-Klone 4.0, Reducing Cell Line Development Time and Cost by Up to 80%

Klone 4.0 accomplishes both in a manner that could potentially disrupt the bioprocessing industry, firstly by reducing development times by up to 80% as AI eliminates many of the laboratory pain points through GBB’s proprietary deep machine learning techniques and algorithms and then by locating those cells with the highest expression capability in record time, in fact, approximately four hours.

Recommended AI News: Avectas Opens Canadian Development Site

Values of Klone 4.0

1. Higher Expression: Deep machine learning and AI intelligent prediction make it easier to find cells with high expression.

2. Up to 12 Times More Cell Line Candidates: Based upon September 2020 customer proof-of-concept data. Twenty-five (25) higher-yielding cell lines were derived using Klone 4.0 as compared to two (2) from a traditional cell line development method from the same cell pool. This surprise result goes beyond industry standards, providing customers with more options and more possibilities. Note: Individual results may vary, depending upon cell pool.

Recommended AI News: Riverbed Promotes Sekhar Kancherlapalli to Chief Information Officer

3. Stability Prediction: In the industry, we have pioneered to utilize deep machine learning to predict cell line stability in a short time.

4. Simple and Cost-effective Process: With “time and cost-saving” written into its DNA, AI delivered extraordinary fruits in cell line development for GBB, and GBB hopes to set a new industry standard and perhaps a new milestone in medicine by – bringing c**** to the market faster while lowering patient costs.

Recommended AI News: CMMI Institute Appraises Genpact at CMMI V2.0 Maturity Level 5